A carregar...
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
PURPOSE: Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS: Fifty-nine adult patients (age 42 to 82 years) with...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4878047/ https://ncbi.nlm.nih.gov/pubmed/23270003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.8623 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|